KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - Other
Ratios

Xenon Pharmaceuticals (XENE) Accumulated Depreciation & Amortization (2016 - 2025)

Xenon Pharmaceuticals (XENE) has disclosed Accumulated Depreciation & Amortization for 12 consecutive years, with $686000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Accumulated Depreciation & Amortization fell 49.3% to $686000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $686000.0, a 49.3% decrease, with the full-year FY2025 number at $686000.0, down 49.3% from a year prior.
  • Accumulated Depreciation & Amortization was $686000.0 for Q4 2025 at Xenon Pharmaceuticals, down from $1.4 million in the prior quarter.
  • In the past five years, Accumulated Depreciation & Amortization ranged from a high of $1.4 million in Q4 2024 to a low of -$2.9 million in Q4 2021.
  • A 5-year average of -$745400.0 and a median of -$542000.0 in 2023 define the central range for Accumulated Depreciation & Amortization.
  • Peak YoY movement for Accumulated Depreciation & Amortization: crashed 220.59% in 2021, then skyrocketed 349.63% in 2024.
  • Xenon Pharmaceuticals' Accumulated Depreciation & Amortization stood at -$2.9 million in 2021, then rose by 21.52% to -$2.3 million in 2022, then surged by 76.4% to -$542000.0 in 2023, then surged by 349.63% to $1.4 million in 2024, then plummeted by 49.3% to $686000.0 in 2025.
  • Per Business Quant, the three most recent readings for XENE's Accumulated Depreciation & Amortization are $686000.0 (Q4 2025), $1.4 million (Q4 2024), and -$542000.0 (Q4 2023).